Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma

Journal of Clinical Oncology

Volumn 27, Issue 26, 2009, Pages 4314-4320

  Kibel, Adam S ^a   Dehdashti, Farrokh ^a   Katz, Matthew D ^a   Klim, Aleksandra P ^a   Grubb, Robert L ^a   Humphrey, Peter A ^a   Siegel, Cary ^a   Cao, Dengfeng ^a   Gao, Feng ^a   Siegel, Barry A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; FUROSEMIDE; DIAGNOSTIC AGENT;

ARTICLE; BLADDER CARCINOMA; BONE SCINTISCANNING; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; CYSTECTOMY; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; PERCUTANEOUS BIOPSY; PRIORITY JOURNAL; URETER CARCINOMA; UROTHELIAL CARCINOMA; ADULT; AGED; BLADDER TUMOR; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; KAPLAN MEIER METHOD; MALE; METHODOLOGY; MIDDLE AGED; MUSCLE; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE CARE; PROGNOSIS; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CYSTECTOMY; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPH NODE EXCISION; MALE; MIDDLE AGED; MUSCLES; NEOPLASM INVASIVENESS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREOPERATIVE CARE; PROGNOSIS; PROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 70349348936     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.6722     Document Type: Article

References (22)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58:71-96, 2008
2. Bellmunt J, Albiol S, Suarez C, et al: Optimizing therapeutic strategies in advanced bladder cancer: Update on chemotherapy and the role of targeted agents. Crit Rev Oncol Hematol 69:211-222, 2009
3. Stein JP, Lieskovsky G, Cote R, et al: Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol 19:666-675, 2001
4. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: A randomised controlled trial-International collaboration of trialists. Lancet 354:533-540, 1999
5. Grossman HB, Natale RB, Tangen CM, et al: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859-866, 2003
6. Neoadjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis. Lancet 361:1927-1934, 2003
7. Winquist E, Kirchner TS, Segal R, et al: Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: A systematic review and meta-analysis. J Urol 171:561-569, 2004
8. Paik ML, Scolieri MJ, Brown SL, et al: Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. J Urol 163:1693-1696, 2000
9. Voges GE, Tauschke E, Stockle M, et al: Computerized tomography: An unreliable method for accurate staging of bladder tumors in patients who are candidates for radical cystectomy. J Urol 142:972-974, 1989
10. Yaman O, Baltaci S, Arikan N, et al: Staging with computed tomography, transrectal ultrasonography and transurethral resection of bladder tumour: Comparison with final pathological stage in invasive bladder carcinoma. Br J Urol 78:197-200, 1996
11. Lantz EJ, Hattery RR: Diagnostic imaging of urothelial cancer. Urol Clin North Am 11:567-583, 1984
12. Buy JN, Moss AA, Guinet C, et al: MR staging of bladder carcinoma: Correlation with pathologic findings. Radiology 169:695-700, 1988
13. Kelloff GJ, Hoffman JM, Johnson B, et al: Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 11:2785-2808, 2005
14. von Schulthess GK, Steinert HC, Hany TF: Integrated PET/CT: Current applications and future directions. Radiology 238:405-422, 2006
15. Jadvar H, Quan V, Henderson RW, et al: [F-18]-Fluorodeoxyglucose PET and PET-CT in diagnostic imaging evaluation of locally recurrent and metastatic bladder transitional cell carcinoma. Int J Clin Oncol 13:42-47, 2008
16. Liu IJ, Segall GM, Nino-Murcia M, et al: Fluorodeoxyglucose positron emission tomography studies in the diagnosis and staging of transitional cell carcinoma. Adv Exp Med Biol 539:129-142, 2003
17. Drieskens O, Oyen R, Van Poppel H, et al: FDG-PET for preoperative staging of bladder cancer. Eur J Nucl Med Mol Imaging 32:1412-1417, 2005
18. Hoekstra CJ, Paglianiti I, Hoekstra OS, et al: Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: An overview of different analytical methods. Eur J Nucl Med 27:731-743, 2000
19. Hillner BE, Liu D, Coleman RE, et al: The National Oncologic PET Registry (NOPR): Design and analysis plan. J Nucl Med 48:1901-1908, 2007
20. Leissner J, Hohenfellner R, Thuroff JW, et al: Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder: Significance for staging and prognosis. BJU Int 85:817-823, 2000
21. Wishnow KI, Johnson DE, Ro JY, et al: Incidence, extent and location of unsuspected pelvic lymph node metastasis in patients undergoing radical cystectomy for bladder cancer. J Urol 137:408-410, 1987
22. Mills RD, Turner WH, Fleischmann A, et al: Pelvic lymph node metastases from bladder cancer: Outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy. J Urol 166:19-23, 2001